RSSDI Repository, Complications of Diabetes Demonstration
RSSDI Repository, Complications of Diabetes Demonstration

Have a Question?

If you have any question you can ask below or enter what you are looking for!

Advanced Search
  • Home/
  • Article /
  • Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.

Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.

Add to Collection
2019 May RCTs B Zinman, V Bhosekar, R Busch, I Holst… - The lancet Diabetes & …, 2019 - thelancet.com

Full Author : ['Zinman, Bernard', 'Bhosekar, Vaishali', 'Busch, Robert', 'Holst, Ingrid', 'Ludvik, Bernhard', 'Thielke, Desiree', 'Thrasher, James', 'Woo, Vincent', 'Philis-Tsimikas, Athena']
Journal Title : The lancet. Diabetes & endocrinology
Chapter : Section25
Journal Year : 2019
Cited by : 215

BACKGROUND: Semaglutide is a once-weekly glucagon-like peptide-1 (GLP-1) analogue for type 2 diabetes. Few clinical trials have reported on the concomitant use of GLP-1 receptor agonists with sodium-glucose cotransporter-2 (SGLT-2) inhibitors. We aimed to..... Read More

Keywords : ['type diabetes sustain', 'randomised placebocontrolle trial', 'inhibitor therapy', 'weekly', 'semaglutide', 'addon']
PubMed Link : https://www.thelancet.com/journals/landia/article/PIIS2213-8587(19)30066-X/fulltext
Google Scholar Link : https://scholar.google.com/scholar?cites=14871655478573559866&as_sdt=40005&sciodt=0,10&hl=en&num=20